






COMPANY PROFILE

Eupraxia is a clinical-stage biotechnology company focused on the development of innovative, locally delivered extended-release products in conjunction with currently approved drugs.

Each of **Eupraxia's** product candidates has the potential to address therapeutic areas with high unmet medical need and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

-  the **Right Dose** of the drug
-  in the **Right Place** for the
-  **Right amount of time**

Intellectual Property Platform

- ✓ Initial patents filed in all major markets with coverage into 2034

MARKET DATA

Exchange: Ticker	TSX: EPRX
Recent Share Price (November 14, 2023)	\$6.72
Common Shares Outstanding (Sep 30, 2023)	27.2 million
Fully Diluted Common Shares (Sep 30, 2023)	42.7 million
Market Capitalization	\$195
52-week Range	\$1.04 - \$9.10
Board & Mgmt. (As of August 11, 2023)	~11% (Basic)/ ~18% (FD)
Cash on Hand (September 30, 2023)	\$33.2 million



THE EUPRAXIA ADVANTAGE


- 1 Significant Near-Term, Value Driving Catalysts**
Product near end of clinical trials & moving closer to potential commercialization
- 2 Robust Pipeline**
Of clinical and non-clinical product candidates
- 3 NASDAQ Listing**
Intention for near-term listing pending market conditions



SCIENCE


Osteoarthritis (OA) is the leading cause of disability in older adults.

Eupraxia's lead candidate, EP-104 has two primary targets identified as knee osteoarthritis and eosinophilic esophagitis (EoE). EP-104 **is designed to improve symptoms and quality of life in all patient populations.**


EP-104 has the potential to be differentiated by dosing, concentrations, delivery vehicle and the route of administration.



-  Traditional extended-release profile
-  Eupraxia targeted release profile
- ✓ Reduced side effects
- ✓ Longer lasting



LEAD CANDIDATE - EP-104IAR / EP-104GI

INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	COMMERCIALIZATION
 EP-104IAR (Osteoarthritis Knee Pain)	[Progress bar showing completion through Discovery, Preclinical, Phase 1, and Phase 2]					
EP-104GI (Eosinophilic Esophagitis)	[Progress bar showing completion through Discovery, Preclinical, and Phase 1]					
EP-104 (Other Inflammatory Conditions) ¹	[Progress bar showing completion through Discovery and Preclinical]					
EP-201 (Post-Surgical Infection) ²	[Progress bar showing completion through Discovery and Preclinical]					
EP-105 (Post-Surgical Pain) ²	[Progress bar showing completion through Discovery and Preclinical]					
Oncology	[Progress bar showing completion through Discovery]					

1 Includes other inflammatory joint conditions, benign strictures of the esophagus, epidural delivery 2. Currently on hold

EP-104IAR - Osteoarthritis (Knee Pain)

- End of Phase 2 meeting with FDA - **Q1 2024**
- Start of Phase 3 study - **H1 2023**
 - Conduct similar trial to build safety database of 500 patients
 - Est. Phase 3 trial length of 24-30 months
 - Focus on U.S. market - BD opportunity outside of U.S

EP-104GI - Eosinophilic

- ✓ Initiate second cohort in Phase 1b/2a clinical trial - **Q4 2023**
- EoE interim data readout - **Q4 2023**
- Proof of concept data - **Q1 2024**
- Pre-IND meeting with FDA - **Q2 2024**
- Sites in the Netherlands, Canada and Australia

LEADERSHIP

JAMES HELLIWELL, MD
CEO & Co-Founder, Director



- Prior to founding Eupraxia, he held a clinical practice at a quaternary academic cardiac center in St. Paul's Hospital, Vancouver. He also served as Clinical Assistant Professor at the University of British Columbia in the Department of Anesthesiology, Pharmacology and Therapeutics
- Medical degree from the University of British Columbia, and Fellowship Certification in Cardiac Anesthesiology and transplantation, and board certification in Perioperative Echocardiography

AMANDA MALONE
CSO & Co-Founder



- 15+ years experience in the development of drug delivery systems. Prior to joining Eupraxia, Dr. Malone was the VP and COO of a drug-delivery focused biotech, Auritec Pharmaceuticals
- PhD in Mechanical and Bioengineering from Stanford University. Bachelor of Science in Engineering from Harvey Mudd College

This presentation does not constitute an offer or invitation to purchase or subscribe for any securities of Eupraxia Pharmaceuticals Inc. (the "Company") and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto. This presentation does not purport to contain all of the information that a prospective investor may require and is not intended to provide any legal, tax, or investment advice. Prospective investors are urged to consult with their own advisors with respect to legal, tax, regulatory, financial, accounting and other such matters relating to any investment in the Company. The safety, efficacy and effectiveness of the Company's products (including EP-104) are still under investigation and market authorization has not yet been granted by Health Canada in Canada or the US Food and Drug Administration in the United States.

FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements and forward-looking information within the meaning of Canadian securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy and objectives, including current and future plans and opportunities, expectations and intentions; the Company's Phase 2 clinical trials; the ability of the Company to execute on its business strategy; the potential of the Company's product candidates; the Company's expectations regarding its product designs, including with respect to patient benefit, duration, safety, effectiveness and tolerability; the results gathered from studies of Eupraxia's product candidates and their potential support for dosing and target population; the Company's beliefs with respect to treatment of knee OA; the Company's initiation of its Phase 3 study; and the Company's planned future milestones and timing thereof. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this presentation may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of the COVID-19 pandemic on the Company's operations; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR (www.sedar.com). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise. All of the forward-looking statements in this presentation are qualified by these cautionary statements and the Company cannot assure that the results or developments anticipated by management will be realized or even if realized, will have the expected consequences to, or effects on, the Company or our business, prospects, financial condition, results of operations or cash flows. Readers are cautioned not to place undue reliance on the forward-looking statements in making any investment decision.

MARKET AND INDUSTRY DATA This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to share value and other data about our industry. The Company has not independently verified any of the data from third party sources referred to in this presentation or ascertained the underlying assumptions relied upon by such sources. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.